Type 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.Load more
Type 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.
In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the overall mortality significantly increased by strict control of blood glucose (target HbA1c <6%) compared with a less stringent control (target HbA1c of approximately 7%). Strict glucose control resulted in a significantly higher likelihood of developing severe hypoglycaemia, while severe hypoglycaemia was itself associated with death due to CVD.Load Less
Type 2 Diabetes Mellitus
CV Outcomes in Diabetes
Risk reduction with antihyperglycemics
Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).
The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.
CV specialists are well-positioned to play a key role in managing patients with T2D including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycemic agents into routine practice.
The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.
National Heart Centre Singapore
Duke-NUS, University Medical Centre Groningen, The George Institute for Global Health
Silvio E Inzucchi, Jeptha P. Curtis, Joseph Gorman, et alCirculation. 2018 Sep 18;138(12):1210-1220.
Milton Packer, Brian Claggett, Martin P. Lefkowitz, et alLancet Diabetes Endocrinol. 2018 Jul;6(7):547-554.
Matthew A Cavender, Anna Norhammar, Kare I Birkeland, et alJ Am Coll Cardiol. 2018 Jun 5;71(22):2497-2506.
Mikhail Kosiborod, Carolyn Ping Su Lam, Shun Kohsaka, et alJ Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639.
Karin Rådholm, Gemma Figtree, Vlado Perkovic, et alCirculation. 2018 Mar 11. pii: CIRCULATIONAHA.118.034222.
Shadi Yaghi, Karen L Furie, Catherine M Viscoli, et alCirculation. 2018 Jan 30;137(5):455-463.
Improved Cardiovascular and Renal Outcomes in the CANagliflozin CardioVascular Assessment Study (CAN...Harold Bays, Luc Van Gaal, S R Aravind, et al
Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration...Lindsay Clegg, Hiddo L Heerspink, Robert C Penland, et al
Tina Vilsbøll, Janusz Gumprecht, Robert J Silver, et al
Identification of Subpopulations Exhibiting the Greatest Cardiovascular Benefit from Long-Acting Glu...Yu Mi Kang, Yun Kyung Cho, Jong Han Choi, et al
Comparative cardiovascular safety and effectiveness of linagliptin in routine care: An interim analy...Elisabetta Patorno, Chandrasekar Gopalakrishnan, Dorothee B. Bartels, et al
No Increased Risk of Heart Failure Hospitalization or Major Cardiovascular Events Observed With Lira...Mansoor Husain, Stephen C Bain, Johannes F E Mann, et al